What's Happening?
Amplitude Vascular Systems (AVS), a medical device startup led by former Boston Scientific executives, is set to significantly expand its workforce in Waltham, Massachusetts. The company has relocated
from the Seaport area to a larger facility at 180 Third Avenue in Waltham, leasing nearly 40,000 square feet from BXP in the CityPoint development. This move is in preparation for the commercialization of its Pulse IVL System, a device designed to treat calcified arteries by emitting pressure waves through a catheter to restore blood flow. Currently, AVS employs about 30 people, primarily engineers, but plans to increase its workforce to 100 by the end of next year. The company anticipates a mid-2026 commercialization date, pending Food and Drug Administration approval.
Why It's Important?
The expansion of AVS in Waltham is significant for the local economy and the medical device industry. By tripling its workforce, AVS is contributing to job creation and economic growth in the region. The development of the Pulse IVL System also represents a potential advancement in the treatment of calcified arteries, offering a new option for patients and healthcare providers. The competition with established devices, such as Johnson & Johnson's Shockwave, highlights the dynamic nature of the medical device market and the ongoing innovation within the sector. This expansion underscores the importance of Waltham as a hub for med-tech companies, attracting talent and investment to the area.
What's Next?
As AVS prepares for the commercialization of its Pulse IVL System, the company will focus on obtaining FDA approval, which is expected by mid-2026. The expansion of its workforce will support the manufacturing, research, and administrative functions necessary for this process. The success of the Pulse IVL System in the market will depend on its ability to compete with existing devices and demonstrate clinical efficacy. Stakeholders, including investors and healthcare providers, will be closely monitoring the company's progress and the regulatory approval process.
